Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zai Lab Ltd.

www.zailaboratory.com

Latest From Zai Lab Ltd.

SOPHIA Positions MacroGenics' Margetuximab For Role In HER2-Positive Breast Cancer

MacroGenics' BLA for full approval in the US is under way and the company already has established a manufacturing facility in preparation for a launch.

Clinical Trials Research and Development Strategies

Hanmi To Step Up Global Drug Development As Lilly Returns BTK Rights

Following Lilly’s decision to return rights to a BTK inhibitor it had licensed in from Hanmi, the South Korean pharma considers independently developing the molecule for other indications and vows to speed up development of other global drug programs.

South Korea Commercial

Asia Deal Watch: BIOCAD, Shanghai Pharma Agree On Pair Of Russian/Chinese Joint Ventures

The JVs will develop and commercialize therapeutics for multiple cancer types and autoimmune disorders in China. Novocure partners its Tumor Treating Fields technology with Zai Lab, while Fate and ONO will collaborate on off-the-shelf CAR-T therapies.

Asia Pacific Deals

Lynparza Blazes PARP Trail In China

AstraZeneca/Merck & Co’s Lynparza has become the first PARP inhibitor to be approved in China, continuing a recent trend of accelerated reviews and approvals for novel therapies from multinationals in the country.

China Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Immune Disorders
  • Inflammation
  • Respiratory, Pulmonary
  • Alias(es)
  • ZAI Laboratory Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Zai Lab Ltd.
  • Senior Management
  • Samantha Du, PhD, Chmn. & CEO
    Billy Cho, CFO
    Jonathan Wang, VP, Head, Bus. Dev.
    William Liang, Chief Commercial Officer
  • Contact Info
  • Zai Lab Ltd.
    Phone: 21 6163 2588
    4560 Jinke Rd., Jinchuang Plaza Bldg. 1
    Zhangjiang Pk.
    Pudong, Shanghai, 201210
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register